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Abstract
Background: Current human papillomavirus (HPV) vaccines that are based on virus-like particles (VLPs) of the major capsid
protein L1 largely elicit HPV type-specific antibody responses. In contrast, immunization with the HPV minor capsid protein
L2 elicits antibodies that are broadly cross-neutralizing, suggesting that a vaccine targeting L2 could provide more
comprehensive protection against infection by diverse HPV types. However, L2-based immunogens typically elicit much
lower neutralizing antibody titers than L1 VLPs. We previously showed that a conserved broadly neutralizing epitope near
the N-terminus of L2 is highly immunogenic when displayed on the surface of VLPs derived from the bacteriophage PP7.
Here, we report the development of a panel of PP7 VLP-based vaccines targeting L2 that protect mice from infection with
carcinogenic and non-carcinogenic HPV types that infect the genital tract and skin.
Methodology/Principal Findings: L2 peptides from eight different HPV types were displayed on the surface of PP7
bacteriophage VLPs. These recombinant L2 VLPs, both individually and in combination, elicited high-titer anti-L2 IgG serum
antibodies. Immunized mice were protected from high dose infection with HPV pseudovirus (PsV) encapsidating a luciferase
reporter. Mice immunized with 16L2 PP7 VLPs or 18L2 PP7 VLPs were nearly completely protected from both PsV16 and
PsV18 challenge. Mice immunized with the mixture of eight L2 VLPs were strongly protected from genital challenge with
PsVs representing eight diverse HPV types and cutaneous challenge with HPV5 PsV.
Conclusion/Significance: VLP-display of a cross-neutralizing HPV L2 epitope is an effective approach for inducing high-titer
protective neutralizing antibodies and is capable of offering protection from a spectrum of HPVs associated with cervical
cancer as well as genital and cutaneous warts.
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Introduction
Human papillomaviruses (HPVs) are non-enveloped viruses
with an icosahedral capsid of 55–60 nm in diameter. The HPV
capsid is composed of 360 copies of the major capsid protein (L1)
and up to 72 copies of the minor capsid protein (L2) which
encapsidate a double-stranded circular DNA genome of about
8 kb [1–4]. HPVs can be divided into over 100 genotypes with
distinct tissue tropisms [5]. Infection with cutaneous HPV types
(such as HPV1, 2, 3, 5, 8, & 10) causes benign cutaneous warts on
normal individuals and on patients suffering from epidermodys-
plasia verruciformis (HPV5). Mucosal HPV types include those
that infect the oral cavity (HPV13), part of the respiratory tract
(especially the throat; HPV6 & 11), and the epithelium of the
anogenital region [6,7]. The anogenital HPVs are further divided
into low-risk and high-risk or carcinogenic HPVs. The low-risk
HPVs (such as HPV6, 11, & 42) cause genital warts whereas the
15–18 high-risk HPVs are associated with cervical cancer. Of the
high-risk HPVs, HPV16 and HPV18 account for approximately
70% of cases of cervical cancer [6,7].
Currently, two prophylactic vaccines have been licensed to
prevent HPV infection. CervarixH (GlaxoSmithKline) and Gar-
dasilH (Merck) contain virus-like particles (VLPs) derived from
HPV16 and HPV18 L1; in addition to these VLPs GardasilH also
contains HPV6 and HPV11 L1 VLPs. Both vaccines are highly
immunogenic and elicit high titer, long-lasting neutralizing
antibody responses. One limitation of these vaccines is that L1
VLPs by and large induce type-specific antibody responses,
meaning that the current L1 VLP-based vaccines provide
protection against a subset of HPV types associated with cancer
and only offer limited cross-protection against other clinically
important carcinogenic HPVs [8–10]. Thus, even vaccinated
women will need to be monitored for HPV infection-related
lesions caused by HPV types not included in the current vaccines.
A nonavalent HPV vaccine consisting of L1 VLPs derived from
HPV6, 11, 16, 18, 31, 33, 45, 52, and 58 is being developed by
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vaccine will provide ,90% protection from infection with high-
risk types, assuming that the vaccine is effective and the increase in
VLP types does not diminish the antibody responses to the four
original VLP types [7]. However, it is unlikely that an L1-VLP
based vaccine could provide complete (100%) protection from all
carcinogenic HPVs.
As an alternative to multitype L1-VLP vaccines, we and others
have been interested in developing pan-HPV vaccines targeting
the HPV minor capsid protein L2. Although L2 is not required to
make VLPs, it is an essential component of infectious virions,
playing roles in virus entry and trafficking of the viral genome to
the nucleus [2]. In its context on native virions, L2 is poorly
immunogenic. Neither natural infection nor immunization with
HPV L1/L2 VLPs elicits anti-L2 antibody responses. However,
vaccination with recombinant L2 protein or peptides derived from
L2 results in the production of neutralizing antibodies that are
protective in animal models [12–16]. This somewhat contradic-
tory data showing that L2 is poorly immunogenic, yet is the target
of neutralizing antibodies, can be explained by recent studies that
shed light on the role of L2 during viral infection. Structural
studies have shown that L2 is poorly exposed on the surface of
virions [2]. However, it has been proposed that after the virus
binds to basement membrane heparin sulfate moieties, the capsid
undergoes a conformational change that exposes the amino
terminus of L2 [17,18]. Once exposed, 12 amino acids at the N-
terminus of L2 are susceptible to proprotein convertase cleavage,
exposing L2 epitopes near the N-terminus of the protein [19].
Antibodies against L2 can interact with this form of the virus, and
prevent the stable interaction between basement membrane-
bound virus and target epithelial cells [20].
Because L2 neutralizing epitopes are exposed transiently,
natural HPV infection fails to elicit anti-L2 neutralizing antibody
responses. Thus, it is likely that there has been little evolutionary
pressure for L2 to undergo antigenic variation. Correspondingly,
amino acid sequence analysis of the amino terminus of HPV L2
reveals a great degree of homology amongst HPV and even animal
papillomavirus types. Immunization with L2 not only elicits
antibodies that are capable of homologous neutralization, but
these antibodies can also neutralize heterologous HPV types
[21,22]. For example, Pastrana et al. demonstrated that an N-
terminal peptide (amino acids 1–88) of bovine papillomavirus type
1 (BPV1) can elicit neutralizing antibodies to BPV1 as well as low
titer cross-neutralizing antibodies to heterologous HPVs such as
HPV6, HPV16, HPV18, and HPV31 [23]. Similar results have
been obtained using short synthetic peptide vaccines. In the late
1990s Kawana et al. observed that a peptide representing HPV16
L2 amino acids 108–120 elicited cross-neutralizing antibodies
against both ‘‘low-risk’’ and ‘‘high-risk’’ HPVs [24,25]. Moreover,
recent studies have shown that sera generated from immunization
with HPV16 L2 peptides can cross-neutralize multitude of HPV
pseudoviruses (PsVs) ranging from cutaneous- to mucosal-
associated HPV types [26,27]. Nevertheless, it is worth noting
that in all these studies high neutralization titers were only
observed with BPV1, HPV16, and HPV18; neutralization titers
against other heterologous HPV PsVs were low. Thus, in general,
the L2 capsid protein is less immunogenic and induces lower titer
neutralizing antibodies compared to VLPs comprised of L1
[22,28,29].
Numerous studies have attempted to increase the immunoge-
nicity of L2. For example, synthetic peptides of cross-neutralizing
epitopes from HPV16 L2 have been conjugated to keyhole limpet
hemocyanin (KLH) or linked to a ubiquitous T helper epitope
[12,26,27,30]. Other studies have displayed these epitopes
genetically on the surface of recombinant BPV1 L1-VLPs
[30,31]. Both strategies increased serum antibody titers but, in
general, the antibodies induced by these peptides only cross-
neutralized subsets of HPV types. As an approach to broaden the
cross-neutralizing antibodies elicited by L2, Jagu et al., designed a
concatenated multimeric L2 fusion protein, which contains amino-
terminal L2 peptides derived from 3 to 22 HPV types [28]. These
vaccines elicited extremely broad neutralizing antibody responses,
although adjuvant was required for optimal neutralization of HPV
PsVs in vivo.
One of the reasonsthat the HPV L1-VLP vaccine is so effective is
that it presents the target antigen (L1) in a highly multivalent format
that is characteristic of the structure of virus particles. VLPs induce
strong antibody responses because the regularity of their capsid
structure presents viral epitopes as dense, highly repetitive arrays,
which are strongly stimulatory to B cells [32]. As such, VLPs have
been exploited as platforms to increase the immunogenicity of
molecules that are poorly immunogenic in their native context [32].
We have recently shown that the genetic display of a broadly cross-
neutralizing epitope of HPV16 L2 (epitope 17–31) on VLPs of the
RNA bacteriophage PP7 elicits high titer antibodies capable of
protecting mice against vaginal challenge with PsV16 and PsV45, a
phylogenetically divergent oncogenic-HPV [33]. Given the immu-
nogenicity of this 16L2 PP7 VLP and the level of protection against
the two PsVs, we decided to explore the immunogenicity of other
types of HPV L2 peptides (17–31) on the same PP7 display platform
with the aim of identifying an immunogen with the broadest
protection and cross-reactivity against other HPV types. Here, we
demonstrate the utility of this approach in eliciting antibody
responses that can protect in vivo against HPV PsVs that represent
diverse HPV-types associated with three different clinical manifes-
tations; cervical cancer, genital warts, and cutaneous warts.
Results
HPV L2 peptides displayed on PP7 VLPs are highly
immunogenic
We have previously shown that a peptide derived from amino
acids 17–31 of HPV16 L2 can be genetically inserted into a
surface-exposed loop of the PP7 bacteriophage coat protein and
that this recombinant coat protein self-assembles into VLPs that
display the L2 peptide on their surface [33]. This epitope from L2
was selected because it is highly conserved amongst HPV types
and it has been shown to contain one or more highly cross-reactive
neutralizing epitopes [12,26]. Sequences encoding this region of
L2 from other HPV types were genetically inserted into PP7 coat
using the same strategy, and these constructs were used to generate
seven additional L2 recombinant VLPs representing sequences
from carcinogenic, genital, and cutaneous HPV types (shown in
Figure 1). The ability of the purified L2 PP7 coat proteins to
assemble into VLPs was observed using a transmission electron
microscope (TEM). As shown in Figure 2, recombinant coat
protein displaying the HPV16 and HPV18 L2 peptides assembled
into VLPs with similar morphology as wild-type PP7 VLPs.
Additionally, the exposure of L2 peptides on the surface of VLPs
was confirmed by ELISA using RG-1, an anti-L2 monoclonal
antibody whose epitope maps to this region of HPV16 L2 [26].
The RG-1 mAb bound to all of the L2 PP7 VLPs, but not with
wild-type PP7 VLP, demonstrating surface exposure of the epitope
(Figure 3). The cross-reactivity of RG-1 which we observed was
much greater than has been previously reported [26]. It is unclear
whether this enhanced binding is a consequence of the multi-
valency of display or the possibility that the VLPs may display the
L2 epitope in a favorable conformation allowing cross-reactivity.
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mice were immunized twice with 5 mg of L2 PP7 VLPs or wild-
type PP7 VLPs. In this experiment, immunizations were
performed using incomplete Freund’s adjuvant (IFA). Sera were
analyzed for anti-L2 IgG by end-point dilution ELISA using five
synthetic disulfide-constrained L2-peptides representing amino
acids 14–40 from HPV1, 5, 6, 16, and 18 as target antigens. Based
on amino acid sequence similarities in this region of L2, the 6L2
peptide was used as target antigen for both 11L2 PP7 VLP- and
58L2 PP7 VLP-derived sera and the 18L2 peptide was used as a
target antigen for the 45L2 PP7 VLP-derived sera. As shown in
Figure 4, all of the L2 PP7 VLPs analyzed in this study were very
highly immunogenic. Geometric mean anti-L2 IgG titers in each
group ranged from 10
4 to 10
5 (except 11L2 PP7 VLP-derived sera
which was somewhat lower; this may reflect the fact that we used a
6L2 peptide to detect anti-L2 antibody responses). No reactivity
was observed with PP7 VLP-derived serum with all the synthetic
L2 peptides tested. Thus, L2 peptides displayed on the surface of
PP7 VLPs display the high immunogenicity that is characteristic of
other VLP-displayed antigens.
Sera generated from HPV L2 peptides is cross-reactive
with L2 from other types of HPVs
As one of our goals was to generate an immunogen with the
broadest cross-reactivity against other HPV types, we tested the
ability of sera from mice immunized with L2 PP7 VLPs to react
with all five synthetic HPV L2 peptides described above (Figure 5).
At the dilution that we tested (1:160), mice immunized with 5, 16,
45, and 58L2 PP7 VLPs showed the broadest cross-reactivity
against the peptides that we tested. Sera from mice immunized
with 6, 11, and 18L2 PP7 VLPs were somewhat less cross-reactive.
Not surprisingly (given the sequence difference of this region), the
least cross-reactivity was observed with the sera from 1L2 PP7
VLP immunized mice. Likewise, only 5L2 PP7 VLP-derived sera,
and to some extent 11L2 PP7 VLP-derived sera cross-reacted with
the HPV1 L2 peptide.
Single L2 PP7 VLPs cross-protect mice from vaginal
challenge with PsV
Since the reactivity level of 16L2 PP7 VLP sera with 16L2
peptide was similar to that with 18L2 peptide, we were interested
to know if mice immunized with 16L2 PP7 VLP will be cross-
protected against genital challenge with PsV18; we were also
interested to know how efficient this protection would be
compared to the protection provided by immunization with
18L2 PP7 VLPs. We assessed whether L2 PP7 VLPs could protect
mice from HPV challenge using the HPV pseudovirus (PsV)
mouse genital challenge model developed by Roberts and
colleagues [34]. After two immunizations with either 16L2 or
18L2 PP7 VLPs, or control non-recombinant wild-type PP7 VLPs,
mice were vaginally challenged with HPV16 or HPV18 PsVs
carrying an encapsidated luciferase reporter gene. Infection was
detected by measuring the expression levels (bioluminescence) of
the luciferase gene encapsidated in the HPV PsV. As shown in
Figure 6, vaccination with either 16L2 or 18L2 PP7 VLPs
completely protected mice from PsV18 infection. Similarly,
immunization with 16L2 and 18L2 PP7 VLPs substantially
protected mice from genital infection with PsV16 (the geometric
mean luciferase signal was 10,000- and 1000-fold lower,
respectively, compared to mice immunized with PP7 VLPs).
These results are consistent with the observed cross-reactivity of
16L2 PP7 VLP sera and 18L2 PP7 VLP sera with 18L2 and 16L2
peptides, respectively (Figure 5).
Sera generated from mixed HPV L2 PP7 VLPs is highly
immunogenic and induces broadly reactive anti-L2 IgG
antibodies
In an attempt to broaden the protection conferred by
vaccination, we also tested the immunogenicity of a combination
vaccine consisting of all eight L2-PP7 VLPs that were constructed.
Mice were immunized with a total of 10 mg of a mixture of 1L2,
Figure 2. Transmission electron micrographs of selected PP7 VLPs. Shown are A) wild-type PP7 VLPs, B) 16L2 PP7 VLPs, and C) 18L2 PP7
VLPs. VLPs were visualized at a magnification of 40,0006.
doi:10.1371/journal.pone.0023310.g002
Figure 1. Amino acid sequence alignment of L2 (residue 17–31,
or equivalent) from selected carcinogenic, genital, and/or
cutaneous HPV types. The consensus sequence was derived from
an alignment of 15 carcinogenic HPVs, 2 genital HPVs, 4 cutaneous
HPVs plus 2 animal papillomaviruses using ClustalW2. Recombinant L2
PP7 VLPs displaying these peptide sequences were constructed. Amino
acids are shown in single-letter code, dots indicate that the amino acid
is identical to consensus sequence, and amino acid differences from the
consensus are shown for each HPV type. A plus (+) symbol indicates
that there is no consensus amino acid at this position.
doi:10.1371/journal.pone.0023310.g001
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L2 PP7 VLPs). As shown in Figure 7, the mixed L2 PP7 VLPs
elicited antibodies with broad reactivity to all five synthetic HPV
L2 peptides that we tested. Geometric mean anti-L2 peptide IgG
end-point dilution titers ranged from a low of 2,560 (for the 1L2
peptide) to .10
5 (for the 6L2 peptide). The trend of reactivity was
similar to that observed with single L2 PP7 VLPs. The highest
reactivity was observed with both 5L2 and 6L2 HPV L2 peptides
followed by 18L2 and 16L2 peptides, likely reflecting the cross-
reactivity between induced antibodies.
Figure 3. Reactivity of the RG-1 monoclonal antibody with recombinant L2 PP7 VLPs. 500 ng of wild-type PP7 VLPs or L2 PP7 VLPs were
used to coat ELISA plates. Binding of a 1:5,000 dilution of RG-1 was detected using a horseradish peroxidase-conjugated goat anti-mouse IgG
secondary antibody followed by development with 2,29-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS). Reactivity was determined by
measuring the mean optical density (OD) values at 405 nm. Error bars indicate standard error of the mean (SEM) of duplicate wells.
doi:10.1371/journal.pone.0023310.g003
Figure 4. Serum IgG antibody responses in mice immunized with individual L2 PP7 VLPs. Mice were immunized i.m. twice with 5 mgo f
PP7 or L2 PP7 VLPs with IFA and their sera collected 2 weeks after the last immunization. Serum anti-L2 IgG titer was determined by end-point
dilution ELISA against streptavidin-conjugated HPV L2 peptides (amino acid 14–40) from HPV1 (squares), HPV5 (inverted triangles), HPV6 (upright
triangles), HPV16 (white-filled circles), and HPV18 (diamonds). Black-filled circles denote reactivity of PP7 sera with the different five L2 peptides. Each
datum point shows antibody titer from each mouse and lines represent the geometric mean titers for each group.
doi:10.1371/journal.pone.0023310.g004
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challenge with diverse HPV pseudoviruses
Given the fact that the broadest L2 peptide reactivity was
observed upon immunization with mixed L2 PP7 VLPs, we asked
whether binding of mixed anti-L2 IgG to HPV L2 peptides
correlated with neutralization in vivo. Mice were immunized three
times with mixed L2 PP7 VLPs and then were vaginally
challenged with eight different HPV PsVs carrying encapsidated
luciferase reporter genes, including one type (PsV31) that was not
a component of our vaccine. As shown in Figure 8, mice
immunized with mixed L2 PP7 VLPs were significantly protected
from all eight PsV types relative to mice immunized with wild-type
PP7 VLPs (all p,0.05, by one-tailed t-test). There was some
variability in the degree of protection. For example, mice
immunized with mixed L2 PP7 VLPs were completely protected
from infection with PsV31 and PsV45. We also observed almost
complete protection from infection with PsV5, PsV18, and PsV52
(except that one mouse in the control group was not infected with
PsV52). Mice immunized with mixed L2 PP7 VLPs and
challenged with PsV6, PsV16, and PsV58 were substantially
(93–99.9% reduction of signal) protected from infection. The lack
of complete protection from these PsV types may partially reflect
Figure 5. Cross-reactivity of sera elicited upon immunization with individual L2 PP7 VLPs with diverse L2 peptides. (A) ELISA plates
were coated with the streptavidin-conjugated L2 peptides described in Figure 4 and reacted with a 1:160 dilution of serum from mice immunized
with wild-type PP7 VLPs or L2 PP7 VLPs followed by secondary antibody. Shown are the averages of the optical density (OD405) values of sera from
three individual mice in each group. Error bars represent SEM. (B) A summary of these results. ‘‘++++’’ indicates a mean OD405.1.2, ‘‘+++’’ indicates a
mean OD405 between 0.8 and 1.2, ‘‘++’’ indicates a mean OD405 between 0.4 and 0.8, ‘‘+’’ indicates a mean OD405 between 0.2 and 0.4, and ‘‘2’’
indicates a mean OD405 below 0.2.
doi:10.1371/journal.pone.0023310.g005
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viruses. Thus, immunization with mixed L2 PP7 VLPs provides
substantial and significant protection from genital challenge by
diverse HPV PsVs.
Immunization with mixed L2 PP7 VLPs protect mice from
cutaneous challenge with PsV5
Due to the fact that HPV5 is associated with cutaneous warts
and the primary site of infection is the skin, we also tested whether
our mixed L2 PP7 VLPs vaccine would also protect against
cutaneous challenge with PsV5. As shown in Figure 9, we observed
very efficient protection; of the two mice immunized with mixed
L2 PP7 VLPs and challenged with PsV5, almost complete
protection from PsV infection was observed compared to the
control group that was immunized with PP7 VLP. Protection
levels were similar to those observed with vaginal challenge.
Discussion
The current licensed HPV vaccines have great potential for
providing protection against the HPV types that are associated
with the majority of cases of cervical cancer and genital warts.
Nevertheless, the fact that these vaccines largely provide
protection against only two of the 15–18 carcinogenic HPVs
means that vaccinated women are still at risk for cancer and will
continue to require HPV DNA and/or Pap testing. Moreover, the
cost of the current vaccines may be a barrier to global
implementation. Thus, it remains a priority to develop an HPV
vaccine that provides broad protection against diverse HPV types
and at a cost that is affordable worldwide.
The largely type-specific protection provided by L1 VLP
vaccines is a significant hurdle to the development of similar L1-
based vaccines that will provide protection against diverse HPVs
associated with all of the clinical manifestations of infection. In
contrast, immunization with L2 elicits broad (but often low titer)
cross-neutralizing antibodies against multiple HPV types [12,21–
23,26,27] and therefore is a potential antigenic target for second-
generation HPV vaccines. We have recently shown that the
display of a broadly neutralizing epitope (L2 17–31) from HPV16
on a bacteriophage PP7 VLP elicits high titer anti-L2 IgG, which
protected and cross-protected mice from vaginal challenge with
PsV16 and PsV45 (an evolutionary divergent HPV), respectively
Figure 7. Immunization with a mixture of L2-PP7 VLPs induces broad anti-L2 IgG responses. Shown is the reactivity of sera from mice
immunized with mixed L2 PP7 VLPs to L2 peptides. Mice were immunized i.m. three times with 10 mg of wild-type PP7 VLPs or 10 mg of mixed L2 PP7
VLPs. Sera were collected 2 weeks after the last immunization and serum anti-L2 IgG titer was determined by end-point dilution ELISA against
streptavidin-conjugated HPV L2 peptides (amino acid 14–40) from HPV1, HPV5, HPV6, HPV16, and HPV18. Black-filled circles denote mice immunized
with PP7 VLPs and diamonds denote mice immunized with mixed L2 PP7 VLPs.
doi:10.1371/journal.pone.0023310.g007
Figure 6. Mice immunized with 16L2 PP7 VLPs or 18L2 PP7 VLPs are protected from vaginal challenge with HPV18 and HPV16 PsV.
Groups of 5 BALB/c mice were immunized i.m. twice with 5 mg of PP7 VLPs, 16L2 PP7 VLPs or 18L2 PP7 VLPs with IFA. Three weeks after the second
immunization, mice were vaginally challenged with 1.3610
5 (PsV18) or 3.0610
6 (PsV16) IU of PsV. Forty-eight hours later, luciferin was instilled
vaginally and images were taken 3 minutes post-luciferin instillation. Images showing the magnitude of vaginal infection with PsV18 or PsV16 are
shown in panels A and B, respectively. The colors reflect the intensity of luciferase expression. Colors are scaled for each image and shown to the right
of the image. Quantitative data (shown in each panel) was extracted by drawing equally sized regions of interests surrounding the site of PsV
instillation and determining average radiance (p/s/cm
2/sr) by using Living Image 3.2 software. Background radiance (determined by gating on
another region of the mouse) was subtracted from this value. Black-filled circles denote mice immunized with control wild-type PP7 VLPs and white-
filled circles denote mice immunized with either 16L2 PP7 VLPs or 18L2 PP7 VLPs. Lines reflect the geometric mean radiance for each group.
doi:10.1371/journal.pone.0023310.g006
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similar epitopes from additional diverse HPV types that range
from oncogenic-, genital-, to cutaneous-associated HPVs. HPV L2
peptides displayed on the PP7 VLP platform in this study were
very immunogenic and elicited high titer anti-L2 antibodies after
only two immunizations. An evaluation of the sera that was
generated in this experiment indicated that there were different
degrees of cross-reactivity with peptides derived from different
HPV types. For example, the sera from mice immunized with L2
sequences from certain carcinogenic HPV types (HPV16, 45, and
58) showed high cross-reactivity with both genital- and cutaneous-
associated HPV types (HPV5 and 6), and vice versa. Among the
HPV L2 peptides that we used, HPV16 has the highest sequence
homology at this epitope with the consensus sequence, which may
Figure 8. Mice immunized with mixed L2 PP7 VLPs are protected from vaginal challenge with diverse PsVs. Groups of 5 Balb/c mice
were immunized i.m. three times with 10 mg of PP7 VLPs or mixed L2 PP7 VLPs. Three weeks after the last immunization, mice were vaginally
challenged with 1.3610
5– 6.5610
6 IU of PsV5, PsV6, PsV16, PsV18, PsV31, PsV45, PsV52, or PsV58. Forty-eight hours later, luciferin was instilled
vaginally and images were taken 3 minutes post-luciferin instillation. Average radiance (p/s/cm
2/sr) values for each animal were determined as
described in Figure 6. Black-filled circles denote mice immunized with wild-type PP7 VLPs and white-filled circles denote mice immunized with mixed
L2 PP7 VLPs.
doi:10.1371/journal.pone.0023310.g008
Figure 9. Mice immunized with mixed L2 PP7 VLPs are protected from cutaneous challenge with PsV5. Balb/c mice were immunized
i.m. as described in Figure 8. Three weeks after the last immunization, mice were subcutaneously challenged in the belly with 6.0610
5 IU of PsV5.
Three days post-challenge, mice were anesthetized and 0.7 mg luciferin was injected subcutaneously. Images of mice immunized with control PP7
VLPs and mixed L2 PP7 VLPs are shown in panels A and B, respectively. Average radiance values for the two groups are shown in panel C. Black-filled
circles denote mice immunized with PP7 VLPs and white-filled circles denote mice immunized with mixed L2 PP7 VLPs.
doi:10.1371/journal.pone.0023310.g009
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Conversely, there was little or no cross-reactivity of other L2 PP7
VLP sera with 1L2 peptide, which has only 53% sequence identity
with the consensus sequence. The little cross-reactivity that was
observed was mostly with 5L2 PP7 VLP sera; both HPV1 L2 and
HPV5 L2 have isoleucine at position 18 of this epitope and this
may suggest that isoleucine at this position is critical for reactivity
with the 1L2 peptide. Based on these observations, we believe a
pan-HPV vaccine from epitope 17–31 of HPV L2 must
incorporate HPV1 L2 peptide given its sequence divergence from
the consensus sequence. Taken together, these results provoked
our use of all eight L2 PP7 VLPs as a mixed VLP vaccine. Despite
the low dose (10 mg total VLPs), this mixed vaccine elicited high
titer, broadly-reactive antibody responses.
Previous studies have documented low titer in vitro cross-
neutralization with different HPV types [12,23,26,28,30,31].
However, in most of these studies, rodents were immunized
multiple times with high doses of antigen and with exogenous
adjuvant. The immune responses observed in this study using PP7
VLPs as a display platform were very high given the fact that only
two doses (5 mg each) were used for VLP immunizations with
individual L2 PP7 VLPs. Moreover, a similar immune response
was observed using a total of 10 mg of our mixed L2 PP7 VLPs.
Furthermore, mixed L2 PP7 VLPs showed the broadest high-titer
reactivity with diverse HPV L2 peptides. It should be noted that
PP7 VLPs encapsidate an endogenous adjuvant, ssRNA, which
can serve as both a TLR7 and TLR8 ligand and is likely to
potentiate antibody responses [35,36].
The immunogenicity of the mixed L2 PP7 VLPs and their
broad reactivity correlated with our in vivo neutralization studies.
Although a few studies have documented neutralization and
cross-neutralization of HPV PsVs both in vitro and in vivo
[12,23,26–28,30,31], to the best of our knowledge, this is the
first study that has looked at in vivo protection of PsVs from 8
diverse HPV types. We observed protection from vaginal
infection by all eight HPV PsVs tested as well as protection
from cutaneous infection with PsV5. Protection from PsV58
infection was somewhat lower compared to other PsV types
tested. This was a little surprising given the fact that efficient
protection from infection was observed with PsV52, which has
the same amino acid sequence as HPV58 at this epitope.
Moreover, serum anti-L2 IgG titers from the two groups of mice
were similar (data not shown). There are three possibilities for this
discrepancy; one could be the doses of the PsV used (which were
somewhat higher with PsV58; 2.3610
6 IU versus 1.3610
5 IU for
PsV52). Another possibility is that this epitope on HPV58 may
not be exposed as readily as that of PsV52. The third formal
possibility is that mixing of the eight L2 PP7 VLPs together may
lead to the induction of both neutralizing and non-neutralizing
antibodies that may compete for PsV binding. However, we
believe that this is unlikely given the protection levels we observed
against PsV18; mixing of 18L2 PP7 VLPs with other L2 PP7
VLPs did not compromise the ability of the vaccine to protect
from PsV18 challenges given the fact that mice immunized with
single 18L2 PP7 VLPs or mixed L2 PP7 VLPs were equally
protected from PsV18 infection.
Notably, we also observed complete protection from infection
by PsV31, which was not included in our vaccine. This data
provides tantalizing evidence of broad cross-neutralization, and we
plan on continuing to assess the potential for broad cross-
neutralization as pseudoviruses from additional HPV types
become available to the scientific community. In summary, our
data suggest that the mixed L2 PP7 VLPs vaccine generated in this
study can serve as a pan-HPV vaccine targeting diverse HPV
types. The phage-VLP approach is effective at low doses, which
will be advantageous for use in resource-poor settings, where the
vast majority of cases of cervical cancer arise.
Materials and Methods
Genetic insertion of L2 peptides into PP7 single-chain
dimer
Two previously described plasmids were used for the synthesis
of L2-recombinant PP7 coat protein in E. coli [33]. The first
(p2P7K32) expresses coat protein from the lac promoter. The
second plasmid type (pET2P7K32) expresses the protein from the
T7 promoter and transcription terminator. Both plasmids contain
an expression cassette that contains a duplicate copy of the PP7
coat protein (the so-called PP7 single-chain dimer) and produce
large amounts of coat protein that assembles correctly into a VLP.
PCR was used to insert HPV L2 peptides (epitope 17–31) into PP7
single-chain dimer of either plasmid as previously described [33].
Forward PCR primers encoded sequences in the following order: a
KpnI restriction site, sequence encoding the L2 amino acids 17–31
(from HPV1, HPV5, HPV6, HPV11, HPV16, HPV18, HPV45,
or HPV58; Figure 1), and a PP7 coat protein sequence that
anneals downstream of the unique KpnI restriction site in the PP7
single-chain dimer [33]. Plasmid p2P7K32 was used as template
and a primer, which anneals downstream of a BamHI restriction
site of p2P7K32 (59-GTTGTAAAACGACGGCCAGT-39) was
used as a reverse primer for all PCR amplifications. PCR
fragments were cloned into either p2P7K32 or pET2P7K32 using
KpnI and BamHI restriction sites. All constructs were confirmed
by sequence analysis.
Expression & purification of L2 PP7 VLPs, TEM, and
antigenic characterization of L2 PP7 VLPs
L2 PP7 VLPs were made by transforming CSH41F or C41 cells
(Lucigen) with plasmids p2P7K32 and pET2P7K32, respectively,
containing L2 peptides from different HPV types. Constitutive
expression of p2P7K32 transformed CSH41F cells was done
overnight at 37uC. C41 cells transformed with pET2P7K32 were
grown at 37uC until they reached an OD600 of 0.6. L2 PP7 protein
expression was induced with 0.5 mM IPTG, grown for an
additional 3 hours, and the culture was centrifuged to pellet the
cells. Cell pellets were lysed and L2 PP7 VLPs were purified from
the soluble fraction as previously described [33]. For TEM
analysis, VLPs were adsorbed on a carbon-coated glow-discharged
copper grids for 2 minutes and were negatively stained with 2%
uranyl acetate for 2 minutes. VLPs were visualized using a Hitachi
H7500 transmission electron microscope at a magnification of
40,0006.
To assess the antigenicity of the L2 PP7 VLPs, 500 ng of
recombinant L2 PP7 VLPs or wild-type PP7 VLPs were used to
coat Immulon 2 ELISA plates (Thermo Scientific) at 4uC
overnight. ELISA procedure was completed as previously
described [33]. Briefly, wells were blocked for 2 hours at room
temperature with 0.5% non-fat dry milk in PBS buffer. Serial
dilutions of monoclonal antibody (RG-1, 1:5,000 dilution,
generously provided by Richard Roden [26]) were added to each
well and incubated for 2 hours at room temperature. Horseradish
peroxidase (HRP)-labeled goat anti-mouse IgG (Jackson Immu-
noresearch, West Grove) at a dilution of 1:5000 was applied for
1 hour as a secondary antibody. The plates were developed with
2,29-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) and
reactivity was determined by measuring the mean optical density
(OD) values at 405 nm.
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anti L2-IgG
All mice work was done in accordance with the National
Institutes of Health and the University of New Mexico
Institutional Animal Care and Use Committee guidelines. In mice
immunized with a single recombinant L2 PP7 VLPs, groups of 3
to 13 Balb/c mice were immunized twice at a two-week interval.
Immunizations were performed intramuscularly (i.m.) using 5 mg
of VLPs plus incomplete Freund’s adjuvant (IFA). In addition,
groups of 5 Balb/c mice were immunized i.m. three times with a
total of 10 mg of mixed L2 PP7 VLPs (all 8 L2 VLPs mixed
together) without IFA. The mixed L2 PP7 VLPs consisted of 2 mg
each of 1L2 and 5L2 VLPs, 2.5 mg of 16L2 VLPs, and 0.7 mg each
of the remaining 5 VLP types. Somewhat higher amounts of 1L2,
5L2, and 16L2 VLPs were added in this mixture because 1L2
VLPs elicited antibodies that were the least cross-type reactive,
and 5L2 and 16L2 VLPs elicited antibody responses that were the
most cross-type reactive (Figure 5). Sera from all experimental
groups were collected two weeks after the last boost and analyzed
by ELISA for anti-L2 IgG.
A peptide-based ELISA was used to assess the titer of anti-L2
IgG in sera. ELISA plates were coated with 500 ng of the
appropriate target peptide (representing L2 amino acids 14–40
from HPV1, 5, 6, 16, and 18; synthesized by Designer Bioscience)
conjugated to streptavidin using a bifunctional cross-linker
(SMPH; Thermo Scientific). The ELISA procedure was complet-
ed as described above, except that dilutions of mouse sera were
used instead of mAb RG-1. Antibody titer was determined as the
reciprocal of the highest sera dilution with an OD405 greater than
2-fold higher than control sera at the same dilution.
HPV pseudovirus production and purification
HPV5, HPV6, HPV16, HPV18, HPV31, HPV45, HPV52, and
HPV58 PsVs with encapsidated reporter plasmid (pClucf)
encoding both luciferase and green fluorescence protein (GFP)
genes were produced in 293TT cells as previously described
[37,38] except that matured PsVs were purified by ultracentrifu-
gation on cesium chloride gradient at 20,000 rpm for 18 hours.
PsV-infectivity titer was characterized using flow cytometry by
determining the fraction of 293TT cells expressing the GFP
protein. L1/L2 expression and reporter plasmids (http://home.
ccr.cancer.gov/lco/packaging.htm) were generously provided by
Chris Buck, Susana Pang, John Schiller, Martin Muller, and
Tadahito Kanda.
Cervicovaginal HPV PsV challenge
Prior to challenge, female Balb/c mice were given two i.m.
immunizations with either 5 mg of 16L2 PP7 VLP, 18L2 PP7
VLP, or PP7 VLP in IFA, or three i.m. immunizations of 10 mg
(total per immunization) of mixed L2 PP7 VLPs (all 8 L2 PP7
VLPs mixed together) or 10 mg of PP7 VLP. Three weeks after the
last boost, mice were treated with 3 mg of Depo-Provera
(Pharmacia Corp). Five days post-Depo-Provera treatment, mice
were vaginally challenged with 1.3610
5– 6.5610
6 infectious units
(IU) of the above PsVs as previously described [34,39]. Forty-eight
hours post-PsV challenge, mice were vaginally instilled with
0.4 mg of luciferin (Caliper Life Sciences) and three minutes later
their images were taken (with a five minute exposure) using a
Caliper IVIS Lumina II (Caliper Life Sciences). Average radiance
(p/s/cm
2/sr) was determined from the images by drawing equally
sized regions of interests surrounding the site of PsV instillation.
Statistical significance was determined by one-tailed paired t-test.
Cutaneous HPV PsV challenge
Balb/c mice were immunized three times as described above
with either PP7 VLPs or mixed L2 PP7 VLPs. Three weeks after
the last immunization, they were challenged as previously
described [12,26,40] with a few modifications. Briefly, mice were
anesthetized, a patch of their belly shaved and they were
challenged subcutaneously on the shaved area of the belly with
6.0610
5 IU PsV5 (the same dose used for cervicovaginal
challenge) in 25 ml of 0.3% carboxymethylcellulose (Sigma-
Aldrich). Three days post-challenged, mice were anesthetized
again and 0.7 mg of luciferin was injected subcutaneously to the
challenged region of the belly. Three minutes later, their images
were taken at 10 minutes exposure with Caliper IVIS Lumina II
(Caliper Life Sciences). Average radiance (p/s/cm
2/sr) was
determined by drawing equally sized regions of interests
surrounding the site of PsV instillation.
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